Global Genome Editing Market 2024-2028

Description

List of Tables

The genome editing market is forecasted to grow by USD 7.23 bn during 2023-2028, accelerating at a CAGR of 15.88% during the forecast period. The report on the genome editing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rapid technological advancements in genome editing, increasing demand for personalized medicine, and the emergence of novel gene editing platforms.

Technavio's genome editing market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	14.56%
CAGR	15.88%
Incremental Value	$7.23bn

By End-user

Pharmaceutical and biotechnology companies
Academic institutes and research laboratories
CRO

By Delivery Mode

Ex-vivo
In-vivo

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the rise of CRISPR-based diagnostics as one of the prime reasons driving the genome editing market growth during the next few years. Also, the growing integration of gene editing with AI and data analytics and increasing adoption of genome editing in agriculture and livestock will lead to sizable demand in the market.

The report on the genome editing market covers the following areas:

Genome editing market sizing
Genome editing market forecast
Genome editing market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading genome editing market vendors that include AstraZeneca PLC, Caribou Biosciences Inc., Cellectis SA, Cibus, Danaher Corp., Editas Medicine Inc., Egenesis, GenScript Biotech Corp., Horizon Discovery Ltd., Intellia Therapeutics Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs Inc., OriGene Technologies Inc., PerkinElmer Inc, Precision BioSciences Inc., Sangamo Therapeutics Inc., Takara Bio Inc., Tecan Trading AG, and Thermo Fisher Scientific Inc.. Also, the genome editing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR45678

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

4.1 Global genome editing market 2018 - 2022
4.2 End-user Segment Analysis 2018 - 2022
4.3 Delivery mode Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition

6 Market Segmentation by End-user

6.1 Market segments
6.2 Comparison by End-user
6.3 Pharmaceutical and biotechnology companies - Market size and forecast 2023-2028
6.4 Academic institutes and research laboratories - Market size and forecast 2023-2028
6.5 CRO - Market size and forecast 2023-2028
6.6 Market opportunity by End-user

7 Market Segmentation by Delivery Mode

7.1 Market segments
7.2 Comparison by Delivery Mode
7.3 Ex-vivo - Market size and forecast 2023-2028
7.4 In-vivo - Market size and forecast 2023-2028
7.5 Market opportunity by Delivery Mode

8 Customer Landscape

8.1 Customer landscape overview

9 Geographic Landscape

9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 UK - Market size and forecast 2023-2028
9.9 Germany - Market size and forecast 2023-2028
9.10 Canada - Market size and forecast 2023-2028
9.11 China - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks

12 Vendor Analysis

12.1 Vendors covered
12.2 Market positioning of vendors
12.3 AstraZeneca PLC
12.4 Caribou Biosciences Inc.
12.5 Cellectis SA
12.6 Cibus
12.7 Danaher Corp.
12.8 Editas Medicine Inc.
12.9 Egenesis
12.10 GenScript Biotech Corp.
12.11 Horizon Discovery Ltd.
12.12 Intellia Therapeutics Inc.
12.13 Merck KGaA
12.14 New England Biolabs Inc.
12.15 Precision BioSciences Inc.
12.16 Sangamo Therapeutics Inc.
12.17 Takara Bio Inc.

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
13.3 Currency conversion rates for US$
13.4 Research methodology
13.5 List of abbreviations